--- title: "Senti Biosciences | 10-Q: FY2026 Q1 Revenue: USD 16 K" type: "News" locale: "en" url: "https://longbridge.com/en/news/286463948.md" datetime: "2026-05-14T20:30:51.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286463948.md) - [en](https://longbridge.com/en/news/286463948.md) - [zh-HK](https://longbridge.com/zh-HK/news/286463948.md) generator: "portal-rs" --- # Senti Biosciences | 10-Q: FY2026 Q1 Revenue: USD 16 K Revenue: As of FY2026 Q1, the actual value is USD 16 K. EPS: As of FY2026 Q1, the actual value is USD -0.14, beating the estimate of USD -0.3333. EBIT: As of FY2026 Q1, the actual value is USD -4.717 M. Senti Biosciences Holdings, Inc. operates as a single reportable segment focused on the research and development of its gene circuit platform technologies, and has not generated any revenue from product sales. #### Collaboration Revenue Collaboration revenue from related parties was $16 thousand for the three months ended March 31, 2026, compared to $0 for the same period in 2025. #### Net Loss Senti Biosciences Holdings, Inc. reported a net loss of - $4.2 million for the three months ended March 31, 2026, which is an improvement from the - $14.1 million net loss for the three months ended March 31, 2025. The accumulated deficit was - $362.8 million as of March 31, 2026, increasing from - $358.6 million as of December 31, 2025. #### Operating Expenses - **Research and Development (R&D) Expenses**: R&D expenses decreased to $5.3 million for the three months ended March 31, 2026, from $9.3 million for the same period in 2025, primarily due to a - $4.0 million decrease in external services and supplies costs. Related party costs within R&D were $282 thousand in 2026, down from $4.07 million in 2025. - **General and Administrative (G&A) Expenses**: G&A expenses were $6.2 million for the three months ended March 31, 2026, a decrease of - $0.9 million from $7.1 million in the prior year, mainly driven by a - $0.7 million decrease in external services and supplies costs. - **Gain on Lease Modification**: The company recognized a one-time gain of $6.9 million on lease modification for the three months ended March 31, 2026, related to the Alameda Lease Amendment. - **Total Operating Expenses**: Total operating expenses decreased to $4.6 million for the three months ended March 31, 2026, from $16.4 million in the prior year. #### Other Income - **Interest Income**: Interest income decreased to $0.1 million for the three months ended March 31, 2026, from $0.4 million in the prior year, attributed to lower average cash balances. - **GeneFab Sublease Income - related party**: Sublease income from related party GeneFab decreased to $0.1 million for the three months ended March 31, 2026, from $1.7 million in the prior year, due to the Alameda Lease Amendment. #### Cash Flow - **Cash and Cash Equivalents**: Cash and cash equivalents were $8.9 million as of March 31, 2026, down from $16.4 million as of December 31, 2025. - **Net Cash Used in Operating Activities**: Net cash used in operating activities was - $7.5 million for the three months ended March 31, 2026, compared to - $14.1 million for the same period in 2025. - **Net Cash Provided by Investing Activities**: Net cash provided by investing activities was $0.1 million for the three months ended March 31, 2026, primarily from the sale of property and equipment. - **Net Cash Used in Financing Activities**: Net cash used in financing activities was - $0.1 million for the three months ended March 31, 2026, mainly due to taxes paid for net settlement of stock awards. #### Unique Metrics & Strategic Summary - **GeneFab Prepaid Expenses**: As of March 31, 2026, $3.3 million of prepayments remained to be amortized against future manufacturing and research activities under the 2024 Amended and Restated DMSA with GeneFab, including $3.4 million in past-due rent converted into an additional prepaid expense. The GeneFab Letter Agreement provides for a $1.4 million back rent payment that can be satisfied via a cash prepayment credit and an additional $2.0 million prepayment credit for work starting September 1, 2026. - **CIRM Grant**: Senti Biosciences Holdings, Inc. received an aggregate of $8.0 million from the California Institute for Regenerative Medicine (CIRM) Grant as of March 31, 2026, to support the clinical development of SENTI-202. - **Liquidity and Going Concern**: The company concluded that its cash and cash equivalents of $8.9 million as of March 31, 2026, were insufficient to continue as a going concern for at least one year, and expects to maintain operations into the third quarter of 2026, assuming receipt of $10.0 million gross proceeds from the initial tranche of senior secured convertible notes in May 2026. Additional funds will be necessary to maintain current operations and continue research and development activities. - **Outlook**: Senti Biosciences Holdings, Inc. anticipates substantially increasing expenses and operating losses in the foreseeable future due to advancing its gene circuit platform, preclinical and clinical development, manufacturing, regulatory approvals, and expanding personnel and intellectual property efforts. - **Subsequent Events (as of April 2026)**: The company completed a holding company reorganization on April 24, 2026. On April 27, 2026, an agreement was entered to issue up to $40.0 million in Senior Secured Convertible Notes in two tranches, with an initial $10.0 million expected in May 2026, where net proceeds of $9.7 million are expected to be used for general corporate purposes, including advancing clinical and manufacturing activities for SENTI-202. The GeneFab Economic Share and GeneFab Option were terminated as of April 2026. ### Related Stocks - [SNTI.US](https://longbridge.com/en/quote/SNTI.US.md) ## Related News & Research - [Senti Biosciences unit issues USD 4 million senior secured convertible notes to Celadon Partners SPV 24](https://longbridge.com/en/news/296532896.md) - [Senti Biosciences to spin off SENTI-202 assets to Celadon-backed NewCo for CVR worth up to $60 million](https://longbridge.com/en/news/292759038.md) - [Senti Biosciences Faces Severe Refinancing and Liquidity Risks from Costly Note Structure](https://longbridge.com/en/news/286635643.md) - [Senti Biosciences Secures Convertible Note Financing with Celadon](https://longbridge.com/en/news/284939423.md) - [Senti Biosciences Q2 net loss narrows to $12.75 million; revenue turns to $17,000](https://longbridge.com/en/news/295971306.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**